Validity of mouse mammary tumour models for human breast cancer: Comparative pathology

Microscopy Research and Technique

Volumn 52, Issue 2, 2001, Pages 224-230

  Cardiff, Robert D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetically engineered mice; Nomenclature; Transplantation; Validation

Indexed keywords

DISEASES; GENETIC ENGINEERING; MAMMALS; TERMINOLOGY; TUMORS;

BREAST CANCER; BREAST LESION; GENETICALLY ENGINEERED MOUSE; HUMAN BREAST CANCER; MAMMARY CANCER; MAMMARY TUMORS; NATIONAL INSTITUTE OF HEALTHS; TRANSPLANTATION; TUMOR MODELS; VALIDATION;

PATHOLOGY;

ANIMAL MODEL; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CANCER GROWTH; CANCER MODEL; CANCER TRANSPLANTATION; FEMALE; GENETIC ENGINEERING; HUMAN; MAMMARY GLAND; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; TERMINOLOGY;

EID: 0035862955     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20010115)52:2<224::AID-JEMT1007>3.0.CO;2-A     Document Type: Review

References (49)

1. Adams JM, Cory S. 1991. Transgenic models of tumor development. Science 254:1161.
2. Amundadottir LT, Johnson MD, Merlino G, Smith GH, Dickson RB. 1995. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Differ 6:737.
3. Andrechek ER, Hardy WR, Siegel PM, Rudnicki MA, Cardiff RD, Muller WJ. 2000. Amplification of the neu/erbB-2 oncogene in a novel mouse model of mammary tumorigenesis. Proc Natl Acad Sci USA 2000 Mar 28;97(7):3444-3449 (see Pub Med http://www.ncbi.n/m.nih.gov:80/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10716706& dopt=Abstract)
4. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. 1989. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:931.
5. Callahan R, Smith GH. 2000. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways [see comments]. Oncogene 19:992.
6. Cardiff RD. 1984. Protoneoplasia: the molecular biology of murine mammary hyperplasia. Adv Cancer Res 42:167.
7. Cardiff RD, Muller WJ. 1993. Transgenic mouse models of mammary tumorigenesis. Cancer Surv 16:97.
8. Cardiff RD, Munn RJ. 1995. Comparative pathology of mammary tumorigenesis in transgenic mice. Cancer Lett 90:13.
9. Cardiff RD, Munn RJ. 1998. The Histopathology of transgenes and knockouts in the mammary gland. In: Heppner G, editor. Breast cancer. JAI Press Inc. Adv Oncobiol :177.
10. Cardiff RD, Wellings SR. 1999. The comparative pathology of human and mouse mammary glands. J Mamm Gland Biol Neoplasia 4:105.
11. Cardiff RD, Sinn E, Muller W, Leder P. 1991. Transgenic oncogenic mice: tumor phenotype predicts genotype. Am J Pathol 139:495.
12. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. 2000. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [see comments]. Oncogene 19:968.
13. Cheung ATW, Young LJT, Chen PCY, Chao CY, Ndoye A, Barry PA, Muller WJ, Cardiff RD. 1997. Microcirculation and metastasis in a new mouse mammary tumor model system. Int J Oncol 11:69.
14. Cory S, Adams JM. 1988. Transgenic mice and oncogenesis. Annu Rev Immunol 6: 25.
15. Dankort DL, Muller WJ. 1996. Transgenic models of breast cancer metastasis. Cancer Treat Res 83:71.
16. Dankort DL, Muller WJ. 2000. Signal transduction in mammary tumorigenesis: a transgenic perspective [see comments]. Oncogene 19:1038.
17. Deng CX, Scott F. 2000. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 19:1059.
18. Dickson C, Creer A, Fantl V. 2000. Mammary gland oncogenes as indicators of pathways important in mammary gland development. Oncogene 19:1097.
19. Green GE, Shibata M-A, Yoshidome K, Liu M-L, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu A-Y, Calvo A, Couldrey C. 2000. The C2(1)/SV40-Tantigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19: 1020.
20. Groner B. 1992. Oncogene expression in mammary epithelial cells [see comments]. J Cell Biochem 49:128.
21. Halter SA, Dempsey P, Matsui Y, Stokes MK, Graves-Deal R, Hogan BL, Coffey RJ. 1992. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. Am J Pathol 140:1131.
22. Jamerson MH, Johnson MD, Dickson RB. 2000. Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models [see comments]. Oncogene 19:1065.
23. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS, Medina D. 2000. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 19:1052.
24. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT. 1990. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61:1137.
25. Kim H, Muller WJ. 1999. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 253: 78.
26. Lee FS, Lane TF, Kuo A, Shackleford GM, Leder P. 1995. Insertional mutagenesis identifies a member of the Wnt gene family as a candidate oncogene in the mammary epithelium of int-2/Fgf-3 transgenic mice. Proc Natl Acad Sci USA 92:2268.
27. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK, 3rd, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. 2000. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20:672.
28. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. 1999. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17:163.
29. Li M, Lewis B, Capuco AV, Laucirica R, Furth PA. 2000a. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene 19: 1010.
30. Li Y, Hively WP, Varmus HE. 2000b. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19:1002.
31. Lin TP, Guzman RC, Osborn RC, Thordarson G, Nandi S. 1992. Role of endocrine, autocrine, and paracrine interactions in the development of mammary hyperplasia in Wnt-1 transgenic mice. Cancer Res 52:4413.
32. Medina D. 1988. The preneoplastic state in mouse mammary tumorigenesis. Carcinogenesis 9:1113.
33. Medina D. 1996. Preneoplasia in mammary tumorigenesis. Cancer Treat Res 83:37.
34. Murphy KL, Rosen JM. 2000. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer [see comments]. Oncogene 19:1045.
35. Nandi S, Guzman RC, Yang J. 1995. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92:3650.
36. Ornitz DM, Cardiff RD, Kuo A, Leder P. 1992. Int-2, an autocrine and/or ultra-short-range effector in transgenic mammary tissue transplants. J Natl Cancer Inst 84:887.
37. Page DL, Dupont WD, Rogers LW. 1986. Breast cancer risk of lobular-based hyperplasia after biopsy: "ductal" pattern lesions. Cancer Detect Prev 9:441.
38. Pattengale PK, Stewart TA, Leder A, Sinn E, Muller W, Tepler I, Schmidt E, Leder P. 1989. Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. Am J Pathol 135:39.
39. Rose-Hellekant TA, Sandgren EP. 2000. Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice [see comments]. Oncogene 19:1092.
40. Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC. 1995. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 55:3915.
41. Schulze-Garg C, Lohler J, Gocht A, Deppert W. 2000. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 19:1028.
42. Smith GH, Sharp R, Kordon EC, Jhappan C, Merlino G. 1995. Transforming growth factor-alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells. Am J Pathol 147:1081.
43. Sternlicht MD, Bissell MJ, Werb Z. 2000. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 19:1102.
44. Vaage J. 1989. A survey of in vivo growth characteristics and spontaneous metastasizing potentials of C3H mouse mammary tumors. Int J Cancer 43:910.
45. Varmus H. 1989. Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis. Ciba Found Symp 142:20.
46. Webster MA, Muller WJ. 1994. Mammary tumorigenesis and metastasis in transgenic mice. Semin Cancer Biol 5:69.
47. Wennbo H, Tornell J. 2000. The role of prolactin and growth hormone in breast cancer [see comments]. Oncogene 19:1072.
48. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. 1999. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 25:293.
49. Young JT. 2000. The cleared mammary fat pad and the transplantation of mammary gland morphological structures and cells. J Mamm Gland Biol Neoplasia (in press).